N. Sicard, S. Squires, Muhammad Mullah, Peter Daley
{"title":"2022 年加拿大接受尼尔马特韦/利托那韦（PaxlovidTM）治疗者的特征和临床疗效：一项描述性队列研究","authors":"N. Sicard, S. Squires, Muhammad Mullah, Peter Daley","doi":"10.14745/ccdr.v49i10a05f","DOIUrl":null,"url":null,"abstract":"statistiques descriptives","PeriodicalId":503267,"journal":{"name":"Relevé des maladies transmissibles au Canada","volume":"68 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Caractéristiques et issues cliniques des personnes traitées avec le nirmatrelvir/ritonavir (PaxlovidMC) au Canada, 2022 : une étude de cohorte descriptive\",\"authors\":\"N. Sicard, S. Squires, Muhammad Mullah, Peter Daley\",\"doi\":\"10.14745/ccdr.v49i10a05f\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"statistiques descriptives\",\"PeriodicalId\":503267,\"journal\":{\"name\":\"Relevé des maladies transmissibles au Canada\",\"volume\":\"68 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Relevé des maladies transmissibles au Canada\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14745/ccdr.v49i10a05f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Relevé des maladies transmissibles au Canada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14745/ccdr.v49i10a05f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Caractéristiques et issues cliniques des personnes traitées avec le nirmatrelvir/ritonavir (PaxlovidMC) au Canada, 2022 : une étude de cohorte descriptive
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
